Population-based lung cancer screening with multislice CT substantially reduces mortality from the disease among high-risk former and current smokers, with larger risk reductions in women vs men, the NELSON study has shown.
Female patients with non-small-cell lung cancer (NSCLC) have markedly better survival than male NSCLC patients, according to the SWOG S0424 study presented at the International Association for the Study of Lung Cancer’s 19th World Conference on Lung Cancer (WCLC 2018).
The use of durvalumab after concurrent chemoradiation (cCRT) therapy reduces the risk of all-cause mortality by 32 percent in patients with unresectable stage III non-small-cell lung cancer (NSCLC), the PACIFIC trial has shown.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.